title: Famciclovir update. Chronic hepatitis B.
abstract: The growing body of preclinical data, as well as clinical data from the phase II doseranging study in immunocompetent patients and from liver transplant recipients participating in the compassionate use program, indicates that famciclovir offers the promise of safe and convenient oral treatment of chronic hepatitis B infection. The results of phase III pivotal studies are eagerly awaited. Denavir is a trademark of SmithKline Beecham plc.
authors.affiliation: SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania 19426-0989, USA.
authors.forename: C L
authors.initials: CL
authors.lastname: Young
mesh_terms: D015075:2-Aminopurine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D000077595:Famciclovir; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D016031:Liver Transplantation; D011355:Prodrugs / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence
chemical_list: D000998:Antiviral Agents; D011355:Prodrugs; D015075:2-Aminopurine; D000077595:Famciclovir